ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Indonesia's Bio Farma says interim data for Sinovac vaccine shows 97% efficacy

Containers with the coronavirus disease vaccines from China's Sinovac Biotech are seen as they arrive at Bio Farma (Persero) in the first shipment to Indonesia in Bandung, Indonesia, Dec. 7.   © Reuters

JAKARTA (Reuters) -- Indonesia's state-owned pharmaceutical company Bio Farma said on Tuesday that interim data on trials it was conducting on vaccines produced by the Chinese company Sinovac showed up to 97% efficacy.

"Our clinical trial team found, within one month, that the interim data shows up to 97% for its efficacy," said Iwan Setiawan, a spokesman for Bio Farma, at a news conference.

He did not elaborate whether the interim result was from a late-stage clinical trial, but another Bio Farma spokesman told Reuters later that the company is still gathering data on efficacy from ongoing Phase 3 trial.

Sinovac had said earlier that 97% of healthy adults receiving lower dosage participating in its Phase 1-2 trial showed antibody-related immune response after taking its COVID-19 vaccine CoronaVac.

A Sinovac spokesman said on Tuesday the company had not received efficacy readings from Phase 3 clinical trials.

Brazil's Butantan Institute biomedical center, which is running a Phase 3 trial of CoronaVac in the country, said last week that Sinovac was expected to publish efficacy results from its vaccine trials by Dec. 15.

Bio Farma did not provide data on how many participants got infected during the trial that involves 1,600 people.

Iwan said Bio Farma would wait for full results and it expected Indonesia's food and drug agency to issue emergency use authorization in late January before mass vaccination could start.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more